Demupitamab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

ichor.bio's Demupitamab Biosimilar (ICH5473) is an unconjugated, non-therapeutic research-grade analog of the originator antibody demupitamab, built around the epidermal growth factor receptor (EGFR, UniProt P00533). It is a human IgG1, kappa molecule intended strictly for research use, not for diagnostic or therapeutic application in humans or animals. As a biosimilar reagent it reproduces the target-binding specificity of the originator drug, providing investigators with a consistent, well-characterised tool for interrogating EGFR biology, benchmarking anti-EGFR binders, and serving as a positive control or reference standard in comparability, epitope-competition, and mechanism-of-action studies. The material is manufactured to research-grade endotoxin specifications (<1 EU/mg), making it suitable for cell-based and functional assays where endotoxin can confound readouts. It is offered in bulk milligram-to-gram quantities to support screening campaigns, assay development, and repeat experiments requiring lot-consistent supply. Because EGFR is a human target, this reagent is typically applied in in-vitro and functional contexts rather than for mouse in-vivo dosing. All framing here is provided for ichor.bio to review before publication. EGFR (epidermal growth factor receptor; ErbB1/HER1, UniProt P00533) is a single-pass transmembrane receptor tyrosine kinase of the ErbB family. Ligand binding (EGF, TGF-alpha, amphiregulin and others) drives receptor homo- or heterodimerisation with other ErbB members, autophosphorylation of the intracellular kinase domain, and activation of downstream RAS-RAF-MEK-ERK, PI3K-AKT, and STAT signalling that governs proliferation, survival, migration, and differentiation. EGFR is frequently overexpressed, amplified, or mutated across epithelial malignancies including non-small-cell lung, colorectal, and head-and-neck cancers, where aberrant signalling promotes tumour growth and therapy resistance. Its extracellular domain is a validated target for antibody-based intervention, and the receptor is a central node in oncology and receptor-signalling research, making anti-EGFR reagents valuable for studying ligand-blocking, dimerisation, internalisation, and antibody-dependent effector mechanisms.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks